GSK2245035
Sponsors
GlaxoSmithKline
Conditions
AsthmaAsthma and RhinitisMild Asthma and Allergic Rhinitis
Phase 2
A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies
CompletedNCT01607372
Start: 2012-04-30End: 2013-09-30Updated: 2017-01-30
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies
CompletedNCT01788813
Start: 2013-03-31End: 2014-08-31Updated: 2014-10-20
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
WithdrawnNCT03707678
Start: 2019-01-21End: 2019-12-23Updated: 2018-10-16